Sterling Capital Management LLC Has $2.76 Million Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Sterling Capital Management LLC reduced its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 16.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,615 shares of the specialty pharmaceutical company’s stock after selling 2,843 shares during the period. Sterling Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $2,763,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JAZZ. Louisiana State Employees Retirement System bought a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $3,327,000. Fifth Third Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 4.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 85 shares during the period. Assenagon Asset Management S.A. bought a new position in Jazz Pharmaceuticals during the first quarter worth $60,496,000. Faithward Advisors LLC raised its stake in Jazz Pharmaceuticals by 31.0% during the 1st quarter. Faithward Advisors LLC now owns 38,339 shares of the specialty pharmaceutical company’s stock valued at $7,717,000 after purchasing an additional 9,065 shares during the last quarter. Finally, XML Financial LLC raised its stake in Jazz Pharmaceuticals by 2.0% during the 1st quarter. XML Financial LLC now owns 6,488 shares of the specialty pharmaceutical company’s stock valued at $1,227,000 after purchasing an additional 127 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $230.02 on Monday. The firm has a market capitalization of $14.45 billion, a PE ratio of -11,495.25, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company’s fifty day moving average price is $224.42 and its two-hundred day moving average price is $192.80. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director directly owned 384,682 shares of the company’s stock, valued at approximately $73,281,921. This represents a 1.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This trade represents a 10.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,098 shares of company stock valued at $2,832,086. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Truist Financial set a $256.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Sixteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.